Background
==========

Sleep changes with advancing age; however, the high prevalence of insomnia in the older adult population is often due to associated age-related medical and psychosocial comorbidities and the frequent use of medications that may impact sleep *per se*\[[@B1]\]. Insomnia symptoms in older adults are frequently associated with daytime fatigue, excessive daytime sleepiness (EDS), and hypnotics use \[[@B2]-[@B4]\]. Insomnia and EDS are also frequently comorbid with other pathologies, notably cardiovascular diseases (CVD) \[[@B5],[@B6]\] and psychiatric disorder, for example, anxiety and depression \[[@B2],[@B4],[@B7]\].

Hypnotics are indicated for treating insomnia symptoms, including those associated with anxiety and depression, and may also be used together with antidepressant treatment. The current use of hypnotics in the general population is estimated to range between 3.5% and 11.7%, doubling in elderly populations \[[@B8]-[@B11]\]. Hypnotics may produce residual daytime sleepiness and impairment of psychomotor, attention and memory performances the day after bedtime administration, especially with the high dose and long half-life durations \[[@B12]\]. Moreover, the use of hypnotics seems to be associated with excess risk of accidents such as falls and car accidents \[[@B12]\] and may increase mortality risk, especially in elderly people with increased pharmacodynamic alterations.

However, the high rate of insomnia, EDS complaints, and psychiatric disorder in the elderly, their frequent comorbidity, and the potential risk of mortality associated with both sleep disorders \[[@B13]\] and psychiatric disorders \[[@B14],[@B15]\] may override hypnotics as the cause of increased mortality, independently of the underlying burden of illness.

Overall, evidence suggesting an association between hypnotics consumption and mortality in the elderly remains controversial. Four observational studies in young adults \[[@B16],[@B17]\] and elderly people \[[@B18],[@B19]\] found no significant associations between hypnotics and all-cause mortality. Other studies reported a significant association with excessive all-cause deaths in adults \[[@B20]-[@B22]\]. Two large studies with very wide age ranges from young adult to older elderly people \[[@B23]-[@B25]\] found significant associations in all age groups, including the elderly. Most of the above studies controlled for sociodemographic characteristics, lifestyle, and some chronic disorders but rarely or not at all for the underlying medical conditions associated with hypnotic prescription, that is depression, antidepressant use, anxiety, insomnia, and EDS. Finally, no studies examined the cumulative effect of hypnotics or the impact of their long-term use on mortality risk in an elderly population specifically. Several methodological issues may contribute to the observed inconsistencies, including the design of the study (retrospective or prospective); the duration of follow-up (between 2.5 and 20 years); the heterogeneity in sample size and age range; the type and duration of hypnotic prescription; and the lack of control for psychiatric and sleep disorders (prescription/indication biases).

The aim of the present study is to examine the associations between the use of hypnotics and 12-year mortality risk (all-causes, cancer and CVD) in a large cohort of community-dwelling elderly people, taking into account a wide range of potential competing risks including sociodemographic characteristics, lifestyle, and chronic disorders as well as underlying psychiatric disorders, EDS, and insomnia complaints. The impact of duration and type of hypnotic treatment were also evaluated.

Methods
=======

Study population
----------------

Participants were recruited as part of the Three-City Study, an ongoing multi-site longitudinal study involving three French cities: Bordeaux, Dijon and Montpellier \[[@B26]\]. Briefly, non-institutionalized participants aged 65 years or over were randomly selected from electoral rolls between 1999 and 2001. The acceptance rate was 37%, yielding a sample of 9,294 individuals.

The study protocol was approved by the ethical committee of the University Hospital of Kremlin-Bicêtre and CPP Sud Méditérannée III, and written informed consent was obtained from each participant. The participants were administered standardized questionnaires and underwent clinical examinations at baseline and after 2, 4, 8, 10 and 12 years.

Mortality
---------

The exact date of death of the participants was obtained from death registries. The causes of death were collected by the local study centers from medical records and interviews with family physicians, clinicians and other non-medical informants (relatives or caregivers) \[[@B27]\]. A validation committee used all information to classify the cause of death using the tenth revision of International Classification of Diseases (ICD-10) \[[@B28]\] as follows: cancer (ICD-10: C00 to C97 and D37 to D48), coronary heart disease and stroke (ICD-10: I00 to I99 and R960 to R961), respiratory (ICD-10: J00 to J99), and ill-defined causes (ICD-10: R00 to R99).

Sociodemographic and clinical variables at baseline
---------------------------------------------------

The standardized interview included questions on demographic characteristics, level of education, living alone, and on health behaviors (for example, consumption of alcohol and smoking status). Information on the health of the participants was obtained through detailed medical questionnaires. Case-level depressive symptoms were defined as a score above the 16-point cut-off on the Center for Epidemiological Studies-Depression Scale \[[@B29]\]. Anxiety trait symptoms were measured using the Spielberger's State-Trait Anxiety Inventory \[[@B30]\]. In the absence of a validated cut-off score in elderly populations, the state score was divided into tertiles with the highest tertile (higher level of anxiety) being compared to the two lowest tertiles. Global cognitive function was assessed by the Mini-Mental State Examination \[[@B31]\] and participants scoring less than 26 were classified as cognitively impaired. Confinement was defined as social restriction (confinement to bed, home or outings restricted to the neighborhood) \[[@B32]\]. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m^2^). The presence of hypertension was defined by measured systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg or current antihypertensive treatment. Diabetes was defined as fasting glucose level ≥7.0 mmol/l or treatment for diabetes. Hypercholesterolemia was defined as total cholesterol level ≥6.2 mmol/L or treatment with lipid-lowering agents. Detailed medical questionnaires included past history of respiratory and thyroid disorders, and cardio-cerebrovascular disease (angina pectoris, myocardial infarction, cardiovascular surgery, arteritis, and stroke) established according to standardized questions.

Sleep complaints at baseline
----------------------------

Sleep complaints were assessed at baseline as part of the clinical interview, followed by the completion of a specific sleep questionnaire \[[@B33]\]. The participants self-rated as 'never, rarely, frequently, or often' occurrence of being excessively sleepy during the day (EDS), having difficulties in initiating sleep (DIS), having several awakenings during the night (difficulties in maintaining sleep; DMS), having early morning awakening (EMA) without being able to go back to sleep, and snoring loudly. In this analysis, EDS was defined as reporting frequently or often being excessively sleepy. Insomnia complaints based on DIS, DMS, and EMA were dichotomized as frequently/often versus never/rarely and summed up to obtain a number of insomnia complaints ranging from 0 to 3. The risk of obstructive sleep apnea syndrome (OSAS) was defined clinically as being obese (BMI ≥30 kg/m^2^), with frequent/often EDS, and frequent/often loud snoring.

Medications and hypnotic use
----------------------------

At baseline and at 2, 4, and 8-year follow-up, an inventory of all prescriptions and over-the-counter drugs used during the preceding month was included in a standardized interview. Medical prescriptions and the medications themselves were checked by the interviewer, thus minimizing exposure misclassification. Current use of antidepressants and hypnotics were coded according to the World Health Organization's Anatomical Therapeutic Chemical Classification \[[@B34]\]. Hypnotics were classified as; benzodiazepines (BZD), BZD-like compounds (zolpidem, zopiclone), and miscellaneous medications (including barbiturates, antihistamines, and other pharmacological categories such as neuroleptics). At baseline, the participants currently taking hypnotics were also requested to report the duration of hypnotic intake.

Statistical analyses
--------------------

Logistic regression models were used to compare the characteristics of participants according to the use of hypnotics at baseline after adjustment for study center, age, and gender. To analyze the associations between hypnotic use and risk of mortality, Cox proportional hazard models with delayed entry and age of the participants as the time scale were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI). This method gives better adjustment for age and is therefore preferable for a sample of elderly individuals over the standard model that uses study time as the time scale, because the covariates are strongly associated with age (for example, chronic diseases) \[[@B35],[@B36]\]. Multivariate models included covariates that were associated with mortality at a conservative level of *P* \<0.15. Model 1 was adjusted for study center, age, and gender. Model 2 was further adjusted for education, alcohol intake, smoking status, BMI, confinement, respiratory disorder, cognitive impairment, history of CVD, hypertension, and diabetes. Two other models were adjusted for diseases associated with hypnotic use to take into account possible prescription bias, for example, number of insomnia complaints and EDS (model 3); and anxiety, depressive symptomatology, and antidepressant use (model 4). The multivariate model 5 was adjusted for all possible confounders. All-cause mortality was the principal outcome defined for the analysis. In secondary analyses, cause-specific mortality due to CVD and cancer was analyzed for separate end points. If both CVD and cancer were reported as cause of death, both causes were considered in the analysis. In all final models, significance level was set at *P* \<0.05. Analyses were performed using SAS statistical software (version 9.2; SAS Inc, Cary, NC, USA).

Results
=======

Study population
----------------

As shown in the study diagram (Figure  [1](#F1){ref-type="fig"}), the study sample included 6,696 participants free of dementia (58.7% women) with a median age of 72.8 years (range, 65.0 to 95.0 years). The 2,382 participants free of dementia excluded from the study were significantly more likely to be older, have a lower education level, were more frequently female and living alone, with confinement, hypertension, diabetes, respiratory disease, hypercholesterolemia, depressive and anxiety symptoms, cognitive impairment, past history of cardio-cerebrovascular disease, and taking more hypnotics (*P* \<0.05 for all comparisons). They were also more likely to have died during the follow-up period (*P* \<0.0001).

![**Flow diagram.**^(1)^ For 41 participants, the cause of death was related to both cardiovascular and cancerb.](1741-7015-11-212-1){#F1}

At baseline, 21.7% of the participants (n = 1,454) were taking at least one hypnotic, 6.9% (n = 464) had three insomnia complaints, and 3.9% (n = 260) had no insomnia complaints. More than 3% (n = 212) reported taking two or more hypnotics. Regarding the main classes of hypnotics, 16% (n = 1070) took BZD, 4.8% (n = 321) BZD-like compounds, and 3.0% (n = 204) miscellaneous medications (of whom 54.4% took antihistamines, 25.0% non-BZD anxiolytics, 18.6% barbiturates, and 4.4% neuroleptics). With regard to duration, 4.8% (n = 304) had been taking hypnotics for less than 5 years, 3.9% (n = 244) between 5 and 10 years, 2.0% (n = 127) between 10 and 20 years, and 6.0% (n = 378) for more than 20 years.

Baseline sociodemographic and clinical characteristics of the participants according to hypnotic use are described in Table  [1](#T1){ref-type="table"}. An analysis adjusted for study center, age, and gender showed that participants taking hypnotics had a lower education level; were more likely to be confined to home; had more symptoms of depression, anxiety, and cognitive impairment; more frequently had a past history of chronic disease (CVD, thyroid disease, diabetes, hypercholesterolemia); consumed less caffeine; and reported more insomnia complaints and EDS (*P* \<0.05 for all comparisons).

###### 

Sociodemographic and clinical characteristics of participants according to hypnotic use at baseline

                                                                 **Hypnotic use**                                                
  -------------------------------------- ----------------------- ------------------ ------- ------- ------- -------------------- ----------
  High level of education^b^             No                      4,136              78.90   1,245   85.63   1                    0.0006
                                         Yes                     1,106              21.10   209     14.37   0.75 \[0.63;0.88\]    
  Living alone                           Yes                     1,610              30.71   605     41.61   1                    0.06
                                         No                      3,632              69.29   849     58.39   0.88 \[0.77;1.01\]    
  Confinement                            No                      5,025              95.86   1,314   90.37   1                    \<0.0001
                                         Yes                     217                4.14    140     9.63    1.90 \[1.51;2.40\]    
  Alcohol intake (g/day)                 \<12                    955                18.22   349     24.00   1                    0.14
                                         12 to 36                3,799              72.47   1,012   69.60   0.86 \[0.75;1.00\]    
                                         \>36                    488                9.31    93      6.40    0.92 \[0.70;1.22\]    
  Caffeine intake (mg/day)               ≤125                    1,310              24.99   423     29.09   1                    0.007
                                         125 to 375              3,103              59.19   836     57.50   0.83 \[0.73;0.95\]    
                                         \>375                   829                15.81   195     13.41   0.76 \[0.62;0.92\]    
  Smoking status                         Never                   3,033              57.86   969     66.64   1                    0.38
                                         Past                    1,901              36.26   402     27.65   0.99 \[0.85;1.15\]    
                                         Current                 308                5.88    83      5.71    1.19 \[0.92;1.55\]    
  History of cardiovascular disease^c^   No                      3,902              74.44   945     64.99   1                    \<0.0001
                                         Yes                     1,340              25.56   509     35.01   1.59 \[1.40;1.81\]    
  Respiratory disease                    No                      4,945              94.33   1,364   93.81   1                    0.35
                                         Yes                     297                5.67    90      6.19    1.13 \[0.88;1.44\]    
  Thyroid disease                        No                      4,823              92.01   1,286   88.45   1                    0.009
                                         Yes                     419                7.99    168     11.55   1.29 \[1.07;1.57\]    
  Depressive symptomatology              No                      4,295              81.93   897     61.69   1                    \<0.0001
                                         Yes                     947                18.07   557     38.31   2.76 \[2.41;3.15\]    
  Antidepressants intake                 No                      5,081              96.93   1,196   82.26   1                    \<0.0001
                                         Yes                     161                3.07    258     17.74   6.32 \[5.12;7.81\]    
  Spielberger trait anxiety              \<43                    3,688              70.35   715     49.17   1                    \<0.0001
                                         ≥43                     1,554              29.65   739     50.83   2.33 \[2.06;2.64\]    
  Mini Mental State Examination Score    ≥ 26                    4,559              86.97   1,190   81.84   1                    \<0.0001
                                         \<26                    683                13.03   264     18.16   1.40 \[1.20;1.65\]    
  Body mass index (kg/m^2^)              Normal (\<25)           2,477              47.25   747     51.38   1                    0.41
                                         Overweight (25 to 29)   2,106              40.18   515     35.42   0.92 \[0.81;1.05\]    
                                         Obese (≥30)             659                12.57   192     13.20   1.00 \[0.83;1.20\]    
  Hypertension                           No                      2,175              41.49   538     37.00   1                    0.08
                                         Yes                     3,067              58.51   916     63.00   1.12 \[0.99;1.27\]    
  Diabetes mellitus                      No                      4,777              91.13   1,314   90.37   1                    0.03
                                         Yes                     465                8.87    140     9.63    1.25 \[1.02;1.54\]    
  Hypercholesterolemia                   No                      3,349              63.89   859     59.08   1                    0.005
                                         Yes                     1,893              36.11   595     40.92   1.19 \[1.05;1.34\]    
  Snoring loudly (n = 5,972)             Never/Rarely            3,021              64.30   863     67.74   1                    0.63
                                         Frequently/Often        1,677              35.70   411     32.26   0.97 \[0.84;1.11\]    
  Difficulties in initiating sleep       Never/Rarely            3,760              71.73   641     44.09   1                    \<0.0001
                                         Frequently/Often        1,482              28.27   813     55.91   2.85 \[2.51;3.24\]    
  Difficulties in maintaining sleep      Never/Rarely            2,029              38.71   455     31.29   1                    \<0.0001
                                         Frequently/Often        3,213              61.29   999     68.71   1.29 \[1.14;1.47\]    
  Early morning awakening                Never/Rarely            3,565              68.01   740     50.89   1                    \<0.0001
                                         Frequently/Often        1,677              31.99   714     49.11   1.85 \[1.64;2.09\]    
  Number of insomnia complaints^d^       0                       1,586              30.26   260     17.88   1                    \<0.0001
                                         1                       1,729              32.98   326     22.42   1.15 \[0.96;1.38\]    
                                         2                       1,138              21.71   404     27.79   2.02 \[1.70;2.41\]    
                                         3                       789                15.05   464     31.91   3.07 \[2.56;3.68\]    
  Excessive daytime sleepiness           Never/Rarely            4,384              83.63   1,165   80.12   1                    0.005
                                         Frequently/Often        858                16.37   289     19.88   1.25 \[1.07;1.47\]    

^a^Adjustment for center study, age and gender; ^b^university level; ^c^history of cardiovascular disease (stroke or coronary heart disease); ^d^number of insomnia complaints: difficulties in initiating sleep + difficulties in maintaining sleep + early morning awakening. CI, confidence interval.

Association between hypnotic use and 12-year mortality
------------------------------------------------------

The median follow-up time for the study was 8.9 years with a range of 0.06 to 11.7 years. During this period, 1,307 (19.5%) deaths were observed. They were particularly related to CVD (26.3%), cancer (36.8%), and co-morbid CVD and cancer (3.1%). A substantial number of deaths were due to ill-defined causes (21.6%) as the result of multiple pathologies associated with frailty, and 10.2% died from respiratory diseases.

Baseline sociodemographic and clinical characteristics in relation to follow-up mortality (all causes) are given in Table  [2](#T2){ref-type="table"}. Participants who died during follow-up were more frequently confined to home, obese, past or current smoker, consuming less alcohol, had hypertension, diabetes mellitus, a past history of CVD, respiratory disease, poorer cognitive performance, EDS, depressive symptoms, or were taking antidepressants. They also tended to have a lower level of education, and more frequently reported insomnia and anxiety symptoms (*P* \<0.15). Subsequent analyses were adjusted for these factors. A significant association was also found for participants at risk of OSAS (n = 133; HR = 1.76; 95% CI = 1.31, 2.36; *P* = 0.0002).

###### 

Baseline predictors of deaths from all causes during follow-up

                                                                 **Deaths-all causes**                                                
  -------------------------------------- ----------------------- ----------------------- ------- ------- ------- -------------------- ----------
  High level of education^b^             No                      4,337                   80.48   1,044   79.88   1                    0.06
                                         Yes                     1,052                   19.52   263     20.12   0.87 \[0.76;1.00\]    
  Living alone                           Yes                     1,782                   33.07   433     33.13   1                    0.84
                                         No                      3,607                   66.93   874     66.87   1.01 \[0.89;1.15\]    
  Confinement                            No                      5,181                   96.14   1,158   88.60   1                    0.0001
                                         Yes                     208                     3.86    149     11.40   1.78 \[1.49;2.13\]    
  Alcohol intake (g/day)                 \<12                    1,062                   19.71   242     18.52   1.23 \[1.06;1.42\]   0.01
                                         12 to 36                3,900                   72.37   911     69.70   1                     
                                         \>36                    427                     7.92    154     11.78   1.14 \[0.96;1.36\]    
  Caffeine intake (mg/day)               ≤125                    1,362                   25.27   371     28.39   1                    0.86
                                         125 to 375              3,164                   58.71   775     59.30   0.97 \[0.85;1.09\]    
                                         \>375                   863                     16.01   161     12.32   0.97 \[0.81;1.17\]    
  Smoking status                         Never                   3,368                   62.50   634     48.51   1                    \<0.0001
                                         Past                    1,740                   32.29   563     43.08   1.22 \[1.07;1.40\]    
                                         Current                 281                     5.21    110     8.42    1.73 \[1.41;2.14\]    
  History of cardiovascular disease^c^   No                      4,079                   75.69   768     58.76   1                    0.0001
                                         Yes                     1,310                   24.31   539     41.24   1.49 \[1.33;1.67\]    
  Respiratory disease                    No                      5,121                   95.03   1,188   90.90   1                    0.0001
                                         Yes                     268                     4.97    119     9.10    1.64 \[1.36;1.98\]    
  Thyroid disease                        No                      4,890                   90.74   1,219   93.27   1                    0.19
                                         Yes                     499                     9.26    88      6.73    1.16 \[0.93;1.45\]    
  Depressive symptomatology              No                      4,209                   78.10   983     75.21   1                    0.0005
                                         Yes                     1,180                   21.90   324     24.79   1.26 \[1.11;1.43\]    
  Antidepressant use                     No                      5,072                   94.12   1,205   92.20   1                    0.0002
                                         Yes                     317                     5.88    102     7.80    1.47 \[1.20;1.80\]    
  Spielberger trait anxiety              \<43                    3,509                   65.11   894     68.40   1                    0.13
                                         ≥43                     1,880                   34.89   413     31.60   1.10 \[0.97;1.23\]    
  Mini Mental State Examination Score    ≥ 26                    4,666                   86.58   1,083   82.86   1                    0.005
                                         \<26                    723                     13.42   224     17.14   1.23 \[1.07;1.43\]    
  Body mass index (kg/m^2^)              Normal (\<25)           2,611                   48.45   613     46.90   1                    0.0007
                                         Overweight (25 to 29)   2,118                   39.30   503     38.49   1.01 \[0.90;1.14\]    
                                         Obese (≥30)             660                     12.25   191     14.61   1.36 \[1.15;1.60\]    
  Hypertension                           No                      2,313                   42.92   400     30.60   1                    0.002
                                         Yes                     3,076                   57.08   907     69.40   1.21 \[1.07;1.36\]    
  Diabetes mellitus                      No                      4,965                   92.13   1,126   86.15   1                    0.0001
                                         Yes                     424                     7.87    181     13.85   1.58 \[1.35;1.85\]    
  Hypercholesterolemia                   No                      3,333                   61.85   875     66.95   1                    0.99
                                         Yes                     2,056                   38.15   432     33.05   1.00 \[0.89;1.12\]    
  Snoring loudly (n = 5,972)             Never/Rarely            3,114                   64.93   770     65.48   1                    0.90
                                         Frequently/Often        1,682                   35.07   406     34.52   1.01 \[0.89;1.14\]    
  Difficulties in initiating sleep       Never/Rarely            3,506                   65.06   895     68.48   1                    0.20
                                         Frequently/Often        1,883                   34.94   412     31.52   0.92 \[0.81;1.04\]    
  Difficulties in maintaining sleep      Never/Rarely            2,055                   38.13   429     32.82   1                    0.26
                                         Frequently/Often        3,334                   61.87   878     67.18   1.07 \[0.95;1.20\]    
  Early morning awakening                Never/Rarely            3,434                   63.72   871     66.64   1                    0.12
                                         Frequently/Often        1,955                   36.28   436     33.36   0.91 \[0.81;1.02\]    
  Number of insomnia complaints^d^       0                       1,526                   28.32   320     24.48   1                    0.07
                                         1                       1,595                   29.60   460     35.20   1.14 \[0.99;1.31\]    
                                         2                       1,227                   22.77   315     24.10   1.08 \[0.92;1.26\]    
                                         3                       1,041                   19.32   212     16.22   0.92 \[0.77;1.11\]    
  Excessive daytime sleepiness           Never/Rarely            4,555                   84.52   994     76.05   1                    0.003
                                         Frequently/Often        834                     15.48   313     23.95   1.23 \[1.07;1.40\]    

^a^Adjusted for center study, gender and age; ^b^university level; ^c^history of cardiovascular disease (stroke or coronary heart disease; ^d^number of insomnia complaints: difficulties in initiating sleep + difficulties in maintaining sleep + early morning awakening.

Table  [3](#T3){ref-type="table"} shows the associations between hypnotic use at baseline and all-cause mortality over the 12-year follow-up. After adjustment for age, gender, and study center, the risk of all-cause mortality increased significantly with the use of any hypnotic, the number of hypnotics, and alone for BZD (*P* \<0.01 for all comparisons, model 1). When potential lifestyle and chronic disorder confounders were entered into the model (model 2), the HR were reduced and failed to be significant except for BZD (*P* = 0.05) and this was unchanged when further adjusting for sleep complaints (model 3). When adjusting for anxiety and depressive symptomatology (model 4), the associations were not significant even for BZD (*P* = 0.22) and this was also the case for the complete multivariate model adjusted for all potential confounders (model 5). BZD-like compounds, and miscellaneous medications intake were not associated with all-cause mortality even in the minimally adjusted model 1. No significant interaction was found for mortality between hypnotic use and EDS, number of insomnia complaints, antidepressant use, chronic diseases, or being at risk for OSAS.

###### 

Risks of death from all causes over 12-year according to hypnotic use

                               **All-cause death**                                                                                                                                                               
  --------------------------- --------------------- ------- ------ ------- -------------------- ------- -------------------- ------ -------------------- ------ -------------------- ------ -------------------- ------
  Hypnotic use                                                                                                                                                                                                   
   No                                 4,261          79.07   981    75.06  1                      0.007 1                      0.16 1                      0.12 1                      0.50 1                      0.43
   Yes                                1,128          20.93   326    24.94  1.19 \[1.05;1.36\]           1.10 \[0.96;1.25\]          1.12 \[0.97;1.29\]          1.05 \[0.92;1.20\]          1.06 \[0.92;1.23\]         
  Number of hypnotics                                                                                                                                                                                            
   0                                  4,261          79.07   981    75.06  1                      0.003 1                      0.13 1                      0.13 1                      0.44 1                      0.47
   1                                   970           18.00   272    20.81  1.14 \[0.99;1.31\]           1.06 \[0.93;1.22\]          1.09 \[0.94;1.26\]          1.02 \[0.89;1.18\]          1.04 \[0.89;1.21\]         
   ≥2                                  158           2.93     54    4.13   1.53 \[1.16;2.01\]           1.32 \[1.00;1.74\]          1.33 \[0.98;1.81\]          1.20 \[0.90;1.60\]          1.21 \[0.88;1.65\]         
  BZD                                                                                                                                                                                                            
   No                                 4,557          84.56   1069   81.79  1                      0.003 1                      0.05 1                      0.05 1                      0.22 1                      0.21
   Yes                                 832           15.44   238    18.21  1.24 \[1.08;1.44\]           1.15 \[1.00;1.33\]          1.17 \[1.00;1.37\]          1.10 \[0.95;1.28\]          1.11 \[0.94;1.30\]         
  BZD-like compounds                                                                                                                                                                                             
   No                                 5,135          95.29   1240   94.87  1                       0.93 1                      0.56 1                      0.76 1                      0.40 1                      0.55
   Yes                                 254           4.71     67    5.13   1.01 \[0.79;1.29\]           0.93 \[0.72;1.19\]          0.96 \[0.74;1.25\]          0.90 \[0.70;1.15\]          0.92 \[0.71;1.20\]         
  Miscellaneous medications                                                                                                                                                                                      
   No                                 5,241          97.25   1251   95.72  1                       0.15 1                      0.30 1                      0.32 1                      0.49 1                      0.49
   Yes                                 148           2.75     56    4.28   1.22 \[0.93;1.60\]           1.15 \[0.88;1.51\]          1.16 \[0.87;1.55\]          1.10 \[0.84;1.45\]          1.11 \[0.83;1.48\]         

^a^Adjusted for age, study center, and gender; ^b^adjusted for age, study center, gender, level of education, confinement, alcohol intake, smoking status, history of cardio and cerebrovascular disease, respiratory disease, Mini Mental State Examination score, body mass index, hypertension, and diabetes mellitus; ^c^adjusted for all the covariates in model 2, plus excessive daytime sleepiness and number of insomnia complaints; ^d^adjusted for all the covariates in model 2, plus depressive symptoms, antidepressant use and Spielberger trait anxiety score; ^e^adjusted for all the covariates in model 3 plus depressive symptoms, antidepressants use and Spielberger trait anxiety score. BZD, benzodiazepines; CI, confidence interval; HR, hazard ratios.

The relationship between hypnotic intake and the risk of mortality remained unchanged after exclusion of the participants who died during the first two years of follow-up (n = 134), the follow-up rate at two years being 88%. With regard to specific causes of death, the use of hypnotics and BZD as well as number of hypnotics were associated with a significantly increased risk of CVD-related death in model 1, but not in the complete multivariate model adjusted for all potential confounders (Table  [4](#T4){ref-type="table"}). There was no significant association between hypnotics and cancer-related death regardless of covariates, even in the minimally-adjusted model 1 (*P* = 0.38).

###### 

Risks of cardiovascular disease and cancer as causes of death over 12 years according hypnotic use

                               **Cardiovascular disease deaths**   **Cancer deaths**                                                                                                                                                        
  --------------------------- ----------------------------------- ------------------- ----- ------- -------------------- ------- -------------------- ------ ------- ------- ----- ------- -------------------- ------ -------------------- ------
  Hypnotic use                                                                                                                                                                                                                              
   No                                        4,962                       78.62         280   72.73  1                     0.02   1                     0.56  4,818    78.04  424    81.23  1                     0.38  1                     0.73
   Yes                                       1,349                       21.38         105   27.27  1.32 \[1.04;1.66\]           0.92 \[0.71;1.20\]          1,356    21.96  98     18.77  0.90 \[0.72;1.13\]          0.96 \[0.74;1.23\]      
  Number of hypnotics                                                                                                                                                                                                                       
   0                                         4,962                       78.62         280   72.73  1                     0.03   1                     0.78  4,818    78.04  424    81.23  1                     0.67  1                     0.94
   1                                         1,154                       18.29         88    22.86  1.26 \[0.99;1.61\]           0.94 \[0.72;1.23\]          1,157    18.74  85     16.28  0.91 \[0.72;1.15\]          0.96 \[0.74;1.25\]      
   ≥2                                         195                        3.09          17    4.42   1.69 \[1.03;2.76\]           0.83 \[0.45;1.52\]          199      3.22   13     2.49   0.89 \[0.51;1.54\]          0.93 \[0.50;1.72\]      
  BZD                                                                                                                                                                                                                                       
   No                                        5,321                       84.31         305   79.22  1                     0.004  1                     0.60  5,170    83.74  456    87.36  1                     0.27  1                     0.42
   Yes                                        990                        15.69         80    20.78  1.45 \[1.13;1.87\]           1.08 \[0.81;1.43\]          1,004    16.26  66     12.64  0.86 \[0.66;1.12\]          0.89 \[0.66;1.19\]      
  BZD-like compounds                                                                                                                                                                                                                        
   No                                        6,008                       95.20         367   95.32  1                     0.65   1                     0.12  5,879    95.22  496    95.02  1                     0.78  1                     0.44
   Yes                                        303                        4.80          18    4.68   0.90 \[0.56;1.44\]           0.67 \[0.40;1.11\]          295      4.78   26     4.98   1.06 \[0.71;1.57\]          1.18 \[0.77;1.82\]      
  Miscellaneous medications                                                                                                                                                                                                                 
   No                                        6,123                       97.02         369   95.84  1                     0.64   1                     0.43  5,986    96.95  506    96.93  1                     0.88  1                     0.95
   Yes                                        188                        2.98          16    4.16   1.13 \[0.68;1.87\]           0.80 \[0.45;1.41\]          188      3.05   16     3.07   0.96 \[0.58;1.59\]          1.02 \[0.59;1.74\]      

^a^Adjusted for age, study center, and gender; ^b^adjusted for all covariates in model 1 plus high level of education, confinement, alcohol intake, smoking status, history of cardio-cerebrovascular disease, respiratory disease, Mini Mental State Examination score, body mass index, hypertension and diabetes mellitus, depressive symptoms, antidepressants use, Spielberger trait anxiety score, excessive daytime sleepiness, and number of insomnia complaints. BZD, benzodiazepines; CI, confidence interval; HR, hazard ratios.

Duration of hypnotic use and mortality
--------------------------------------

Sensitivity analyses were performed to examine the relationship between persistent use of hypnotics during the initial 4 years and all-cause mortality. A total of 3,496 participants (65.9%) did not report hypnotic use at baseline or at follow-up examination, 773 (14.5%) reported use both at baseline and at the first two follow-ups (persistent users) and 1,040 (19.6%) were taking hypnotics at one of two time points (intermittent users). The risk of mortality for the next 8 years was not significantly associated with the persistent use of hypnotics (when compared with non-users, HR = 1.03, 95% CI = 0.84, 1.28 for intermittent users; HR = 1.11, 95% CI = 0.88, 1.39 for persistent users; multivariate model 5). Similar results were obtained when the analyses focused on persistent BZD users in comparison to non persistent BZD users or non BZD users.

We also examined the impact of past hypnotic intake duration and compared participants who were not taking sleep medication at baseline with those having previously reported taking sleep medications for less than 5 years, between 5 and 10 years, between 10 and 20 years, and for more than 20 years. No significant association was observed between duration of hypnotic intake and all-cause mortality, the global *P*-value ranging from 0.18 (model 1) to 0.76 (model 5) (data not shown).

Discussion
==========

This study examined associations between hypnotic intake and risk of excess mortality (all-causes and specific causes) over a 12-year period in a large elderly cohort, taking into account a wide range of potential confounding factors. As in several previous studies we observed significant associations between hypnotic use, notably BZDs, and mortality; however, these associations became non-significant after adjustment for all potential confounding factors, notably psychiatric disorder. These findings persisted even after taking into account up to 20 years duration of past hypnotic intake or persistent versus intermittent use.

Previous studies have been inconsistent, with some studies observing significant relationships between hypnotic prescriptions and mortality \[[@B16],[@B20]-[@B25],[@B37]\] and others not \[[@B16]-[@B19]\]. Our findings suggest that these differences are probably largely due to failure to take into account confounding associations, notably common affective symptoms and sleep complaints, although other factors such as study design, participant age, and class of hypnotics probably also influence study outcome.

Insomnia symptoms often lead to the use of hypnotics, a condition frequently associated with EDS, anxiety, and mood disorders. Depression and anxiety are also risk factors for mortality \[[@B14],[@B15]\]. Depressive symptomatology and insomnia are both common in the elderly and in France there are no official guidelines for management, so antidepressants are often used to treat sleep disorder and hypnotics to treat depression, especially where sleep disturbance is one of the presenting symptoms \[[@B2]\]. EDS is also of multifactorial origin, and commonly associated with depression \[[@B7]\], cognitive decline \[[@B38]\], physical illness (particularly CVD), and mortality in older adults \[[@B5],[@B6],[@B13]\]. Thus, all these conditions may increase the risk of mortality in elderly patients through pathways independently of hypnotics. However, few previous studies have controlled for psychological status \[[@B17],[@B18],[@B22],[@B23]\] and in studies where depressive symptoms have been considered, antidepressant use has not been necessarily taken into account. This is important because antidepressant use may relieve depressive symptomatology, but the underlying biological risk factors associated with increased mortality may still be operating. No previous studies have controlled for anxiety or simultaneously for insomnia and EDS symptoms as potential independent confounding factors. To our knowledge, our study is the first one controlling for such a large range of potential confounding factors, especially the underlying diseases associated with hypnotic use, such as anxiety and depressive symptomatology and antidepressant use, as well as EDS and insomnia complaints. Our finding that psychiatric disorder could be a principal determinant driving the association between hypnotics and mortality risk explains previous inconsistencies.

Chronic use of hypnotic drugs, particularly BZD, may be associated with the risk of addiction and insomnia-rebound after withdrawal, psychomotor impairment and cognitive problems, OSAS, EDS, and car accidents \[[@B12],[@B39],[@B40]\]. In our sample, only one participant died from a car accident, and this person did not use hypnotics. We did not find any interaction between individuals clinically at risk for OSAS, hypnotics intake, and mortality, suggesting that if hypnotics trigger or aggravate OSAS they do not impact on mortality risk. The use of BZD may also favor falls and hip fractures and thus increase the risk for disability and death especially in the elderly \[[@B41],[@B42]\]. However some studies have suggested that nighttime sleep problems may also be significant risk factors for falls in the elderly, independently of hypnotic use \[[@B43]-[@B45]\]. In our study, the associations between hypnotic use and all-causes or CVD-related death became non-significant after adjustment for health behavior and status variables, plus EDS and insomnia complaints.

An increased incidence risk for cancer was also reported in individuals using hypnotics in some studies \[[@B21],[@B22],[@B24]\], even in infrequent hypnotic users \[[@B22]\]. Our study did not report any association between hypnotic use and cancer-related death. Again, differences in adjustment of underlying co-morbid conditions frequently associated with the chronic use of hypnotics appear to explain previous findings.

The present study has some limitations. Unfortunately, data related to hypnotic dose were not available. Bias could have been introduced by the low participation rate at baseline and the non-random exclusion of participants with missing data at baseline -- these participants were older, were more commonly hypnotics users, and more often had psychiatric and other chronic disorders that may limit the generalizability of our findings. Although unlikely, the possibility of overadjusment can not be excluded: potential confounding variables should be intermediate variables in the causal pathway between hypnotics intake and mortality. Finally, the absence of significant association between the use of hypnotics and mortality (all-causes, and CVD) after adjustments for covariates should be interpreted with caution regarding the small number of events per predictor variable.

Our prospective study based on a large community sample has several strengths, including the duration of the follow-up and adjustment for a wide range of possible confounding factors including sociodemographic and lifestyle factors, chronic disorders, and sleep complaints as well as depression and anxiety disorders that were found as key confounding factors in this study. Prescriptions and medications themselves were checked by the interviewer and the causes of death were established by an independent committee. Finally, excluding participants who died during the first two years of follow-up did not modify the main results, suggesting a modest confounding effect of severe undiagnosed conditions in relation to hypnotic use and death.

Conclusions
===========

Our findings suggest that the use of hypnotics is not independently associated with an increased risk of mortality in the elderly, and that previous findings may be largely attributable to failure to take into account confounding variables, notably clinical co-morbidity, which is frequent at higher ages, particularly psychiatric disorders. Use of hypnotics might be a marker underlying more complex health issues.
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